BioGenCell

📢 We're proud to be featured in the latest CTech by Calcalist release, focusing on BioGenCell LTD's groundbreaking cell therapy technology for microvascular disease: https://lnkd.in/d4ph7FGN
🤝 A huge thank you to our partners, investors, and advisors for your 𝐮𝐧𝐰𝐚𝐯𝐞𝐫𝐢𝐧𝐠 support!

🙏 A special thank you of course to Marius Nacht and his great team Uri Yaron and Shoham , whose $𝟏𝟔𝐌 investment is the wind in the wings of our phase 2 trial.
And Kudos to the BioGenCell LTD team for their dedication and hard work.

From the article: “Our mission is to improve quality of life and not just extend it. The same patient after treatment can after a few months walk, function, and live without pain.” Dr. Yael Porat. This is why we do what we do, and we are fortunate to have so many wonderful people committed to this journey.

If you or someone you know suffers from Critical Limb Threatening Ischemia and is at risk of losing their limb, do not hesitate to contact us: https://lnkd.in/eBa5Dcbp

https://www.calcalistech.com/ctechnews/article/hki11xl2wa

BioGenCell pioneers revolutionary cell therapy for microvascular disease | CTech CEO Yael Porat spoke to CTech about the Israeli biotech company’s groundbreaking cell therapy technology for the common and debilitating disease whose primary treatment today is amputation

The NY24 NYSPMA conference kicks off today! 👣 Join us at booth #114!
BioGenCell LTD is excited to showcase our multinational Phase 2 clinical trial, focusing on Chronic Limb-Threatening Ischemia. We'll be diving into our groundbreaking TRACT technology, which leverages a patient's blood to regenerate microvasculature, **showing significant potential in preventing amputations.**

Meet us at booth #114 to learn more about our innovative approach and explore potential collaborations. For detailed information, visit our website:
https://www.biogencell.net/clinical-trials/
and the NIH clinical trials page: [NCT02805023](https://lnkd.in/dzDSJqfn).

Looking forward to engaging discussions and meaningful collaborations at the conference! 🙌

Clinical Trials - BioGenCell Join a Journey that Brings New Hopeto No-Option Patients BioGenCell’s Phase 2 Clinical Trial for BGC 101Double blind randomized placebo controlled study to assess the feasibility of BGC101(EnEPC) in treating Critical Limb Ischemia. Clinical trial Gov identifier: NCT02805023 Previous image Next ima...

📢 BioGenCell LTD proudly announces the launch of our Phase 2 Clinical Trial for BGC 101 at the University of Maryland Medical Center in the U.S. This pivotal study is a double-blind, randomized, placebo-controlled trial, aiming to assess the effectiveness of BGC101(EnEPC) in treating Critical Limb Ischemia.
In these challenging times, our commitment to advancing medical care and improving patient outcomes remains strong. Stay tuned for further updates on this trial > https://lnkd.in/epRrSa4Q
https://lnkd.in/dEdzSHAc
https://finance.yahoo.com/news/biogencell-announces-launch-biogencells-fifth-180000201.html

BioGenCell Announces the Launch of BioGenCell's Fifth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States BioGenCell, a pioneer in personalized cell therapy solutions, is excited to announce the launch of its fifth Phase II clinical trial site in the United States at the University of Maryland Medical Center. The trial is focused on significantly reducing the need for amputation in patients with Chronic...

📢 We're proud to announce BioGenCell's Phase II clinical trial site! Following Yale University, University of California San Francisco and Johns Hopkins Medicine. Westchester Medical Center is the fourth USA site of BioGenCell's international trial targeting Chronic Limb-Threatening Ischemia (CLTI) patients.
https://lnkd.in/eHGQMmM2

👉 For participation details, visit: https://lnkd.in/epRrSa4Q

We're excited to announce the launch of the first-ever BioGenCell's cell-therapy Chronic Limb-Threatening Ischemia (CLTI) clinical trial in Europe, at of Thoracic and Vascular Surgery UZG!
Do you or someone you know suffer from CLTI (also known as CLI) - Join us on this groundbreaking journey or help us spread the word!
👉 To our website https://lnkd.in/eQCBmhch